相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The dopamine D3 receptor, a quarter century later
Pierre Sokoloff et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2017)
Pharmacokinetics and Safety Assessment of L-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study
Hazem E. Hassan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers
Stig Evensen et al.
SCHIZOPHRENIA BULLETIN (2016)
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Jeffrey A. Lieberman et al.
BIOLOGICAL PSYCHIATRY (2016)
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
Leslie Citrome
CNS SPECTRUMS (2016)
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Robert E. Davis et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Impact of Cognitive and Social Cognitive Impairment on Functional Outcomes in Patients With Schizophrenia
Michael F. Green
JOURNAL OF CLINICAL PSYCHIATRY (2016)
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Robert E. Davis et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Treatment-Resistant Schizophrenia
Helio Elkis et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2016)
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
Takashi Uehara et al.
CURRENT NEUROPHARMACOLOGY (2015)
ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers
Robert E. Davis et al.
PSYCHOPHARMACOLOGY (2015)
Glutamatergic agents for schizophrenia: current evidence and perspectives
Mathias Zink et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2015)
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Wei Hu et al.
YEAR IN NEUROLOGY AND PSYCHIATRY (2015)
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Gretchen L. Snyder et al.
PSYCHOPHARMACOLOGY (2015)
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials
Paolo Fusar-Poli et al.
SCHIZOPHRENIA BULLETIN (2015)
Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review
G. Fond et al.
ACTA PSYCHIATRICA SCANDINAVICA (2014)
Emerging drugs for schizophrenia: an update
Luisa-Sophie Koester et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials
Naren P. Rao et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Simultaneous determination of L-tetrahydropalmatine and cocaine in human plasma by simple UPLC-FLD method: Application in clinical studies
Mingming Yu et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2014)
L-Tetrahydropalmatine inhibits methamphetamine-induced locomotor activity via regulation of 5-HT neuronal activity and dopamine D3 receptor expression
Jaesuk Yun
PHYTOMEDICINE (2014)
Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole: Distinctive Clinical Characteristics of 5 Novel Atypical Antipsychotics
Sheng-Min Wang et al.
CLINICAL NEUROPHARMACOLOGY (2013)
l-Isocorypalmine reduces behavioral sensitization and rewarding effects of cocaine in mice by acting on dopamine receptors
Wei Xu et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials
Naren P. Rao et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Dopamine D3 receptor antagonism-still a therapeutic option for the treatment of schizophrenia
Gerhard Gross et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2013)
A serotonin hypothesis of schizophrenia
Arnold E. Eggers
MEDICAL HYPOTHESES (2013)
Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response
A. Bhathena et al.
TRANSLATIONAL PSYCHIATRY (2013)
Pharmacogenomics can improve antipsychotic treatment in schizophrenia
Qingqing Xu et al.
FRONTIERS OF MEDICINE (2013)
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia
Mark E. Schmidt et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
BL-1020, a New γ-Aminobutyric Acid–Enhanced Antipsychotic
Yona Geffen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681
Erik T. te Beek et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
Carrie K. Jones et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day
Herbert Y. Meltzer et al.
SCHIZOPHRENIA RESEARCH (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Jan Kehler et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia
Laura Redden et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Contribution of SPECT Measurements of D2 and 5-HT2A Occupancy to the Clinical Development of the Antipsychotic SB-773812
Ana M. Catafau et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925
Ariel Graff-Guerrero et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures
Mark J. Millan et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Effects of benzodiazepine treatment on cortical GABAA and muscarinic receptors: Studies in schizophrenia and rats
Mark C. McLeod et al.
PSYCHIATRY RESEARCH (2010)
BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia
Yona Geffen et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans
Lieuwe Appel et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Christoph U. Correll et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
The Dopamine Hypothesis of Schizophrenia: Version III - The Final Common Pathway
Oliver D. Howes et al.
SCHIZOPHRENIA BULLETIN (2009)
Schizophrenia, just the facts 4. Clinical features and conceptualization
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2009)
Verbal working memory dysfunction in schizophrenia: An fMRI investigation
Chi-Un Pae et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2008)
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects
Abraham Nudelman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: Implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function
Henry Sershen et al.
NEUROCHEMISTRY INTERNATIONAL (2008)
S33138 (N-[4-[2-[(3aS, 9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent:: III.: Actions in models of therapeutic activity and induction of side effects
Mark J. Millan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia
Yechiel Levkovitz et al.
BRAIN RESEARCH (2007)
Glutamate and schizophrenia: Beyond the dopamine hypothesis
Joseph T. Coyle
CELLULAR AND MOLECULAR NEUROBIOLOGY (2006)
An update of fast-off dopamine D2 atypical antipsychotics
P Seeman
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
PJ Harrison et al.
MOLECULAR PSYCHIATRY (2005)
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies
CU Correll et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Amisulpride - A review of its use in the management of schizophrenia
K McKeage et al.
CNS DRUGS (2004)
Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?:: A new hypothesis
S Kapur et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
A separate disease within the syndrome of schizophrenia
B Kirkpatrick et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
J Geddes et al.
BRITISH MEDICAL JOURNAL (2000)
分享论文
